{"title": "Planning all-oral, once-daily regimen, J&J gets EMA backing for Imbruvica-venetoclax combination", "author": "Nick Paul Taylor", "url": "https://www.fiercepharma.com/pharma/planning-all-oral-once-daily-regimen-jj-gets-ema-backing-imbruvica-venetoclax-combination", "hostname": "fiercepharma.com", "description": "Johnson & Johnson is a step closer to realizing its vision of creating an all-oral, once daily, fixed-duration treatment regimen for chronic lymphocytic leukemia (CLL) patients. | Johnson & Johnson is a step closer to realizing its vision of creating an all-oral, once daily, fixed-duration treatment regimen for chronic lymphocytic leukemia (CLL) patients. The Big Pharma's strategy advanced last week when the European Medicines Agency's (EMA) drug review committee backed the candidate.", "sitename": "FiercePharma", "date": "2022-06-28", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}